Activated Prothrombin Complex Concentrates (aPCCs)

Activated prothrombin complex concentrates (aPCCs; factor VIII inhibitor bypassing activity [FEIBA]) contain mainly nonactivated therapeutic levels of factor II, IX, and X and mainly activated factor VII (VIIa).

Indications Top

1. Treatment of bleeding in individuals with congenital hemophilia A complicated by an inhibitor, who are not treated with emicizumab, and with acquired hemophilia A.

2. Off-label use: Intracranial hemorrhage, pentasaccharide-mediated (eg, fondaparinux) bleeding, life-threatening bleeding associated with non–vitamin K antagonists, reversal of dabigatran in patients who require urgent procedure (if idarucizumab is unavailable). 

aPCCs carry a prothrombotic risk and should only be administered in situations where the benefit of the therapy outweighs this risk.